Vaxxim - Articles and news items

First patient treated in Phase I VXM01 glioblastoma trial

Industry news / 13 July 2016 / Victoria White, Digital Content Producer

Vaximm’s VXM01 is a oral T-cell immunotherapy that targets the tumour-specific vasculature and certain immune-suppressive cells…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+